Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jul 18, 2024
- Pharmaceuticals
- R&D
Roche Announces Vabysmo’s Long-Term Diabetic Macular Edema Study Data
TOKYO, July 18, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that F. Hoffmann-La Roche Ltd (Head Office: Basel, Switzerland. CEO: Thomas Schinecker) issued a Media Release today, regarding four-year data from the RHONE-X extension study of Vabysmo® (generic name: faricimab) in diabetic macular edema (DME).
Please refer to the link below for details of the Roche’s Media Release:
Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study
https://www.roche.com/media/releases/med-cor-2024-07-17b
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
